These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 34850124)

  • 1. Efficient DNA interrogation of SpCas9 governed by its electrostatic interaction with DNA beyond the PAM and protospacer.
    Zhang Q; Chen Z; Wang F; Zhang S; Chen H; Gu X; Wen F; Jin J; Zhang X; Huang X; Shen B; Sun B
    Nucleic Acids Res; 2021 Dec; 49(21):12433-12444. PubMed ID: 34850124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Why Does the E1219V Mutation Expand T-Rich PAM Recognition in Cas9 from
    Bhattacharya S; Satpati P
    J Chem Inf Model; 2024 Apr; 64(8):3237-3247. PubMed ID: 38600752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous evolution of SpCas9 variants compatible with non-G PAMs.
    Miller SM; Wang T; Randolph PB; Arbab M; Shen MW; Huang TP; Matuszek Z; Newby GA; Rees HA; Liu DR
    Nat Biotechnol; 2020 Apr; 38(4):471-481. PubMed ID: 32042170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular basis for the PAM expansion and fidelity enhancement of an evolved Cas9 nuclease.
    Chen W; Zhang H; Zhang Y; Wang Y; Gan J; Ji Q
    PLoS Biol; 2019 Oct; 17(10):e3000496. PubMed ID: 31603896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The post-PAM interaction of RNA-guided spCas9 with DNA dictates its target binding and dissociation.
    Zhang Q; Wen F; Zhang S; Jin J; Bi L; Lu Y; Li M; Xi XG; Huang X; Shen B; Sun B
    Sci Adv; 2019 Nov; 5(11):eaaw9807. PubMed ID: 31763447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineered dual selection for directed evolution of SpCas9 PAM specificity.
    Goldberg GW; Spencer JM; Giganti DO; Camellato BR; Agmon N; Ichikawa DM; Boeke JD; Noyes MB
    Nat Commun; 2021 Jan; 12(1):349. PubMed ID: 33441553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Mechanism of D1135E-Induced Discriminated CRISPR-Cas9 PAM Recognition.
    Kang M; Zuo Z; Yin Z; Gu J
    J Chem Inf Model; 2022 Jun; 62(12):3057-3066. PubMed ID: 35666156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural insights into a high fidelity variant of SpCas9.
    Guo M; Ren K; Zhu Y; Tang Z; Wang Y; Zhang B; Huang Z
    Cell Res; 2019 Mar; 29(3):183-192. PubMed ID: 30664728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolved Cas9 variants with broad PAM compatibility and high DNA specificity.
    Hu JH; Miller SM; Geurts MH; Tang W; Chen L; Sun N; Zeina CM; Gao X; Rees HA; Lin Z; Liu DR
    Nature; 2018 Apr; 556(7699):57-63. PubMed ID: 29512652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genome editing mediated by SpCas9 variants with broad non-canonical PAM compatibility in plants.
    Li J; Xu R; Qin R; Liu X; Kong F; Wei P
    Mol Plant; 2021 Feb; 14(2):352-360. PubMed ID: 33383203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of genetically modified mice using SpCas9-NG engineered nuclease.
    Fujii W; Ito H; Kanke T; Ikeda A; Sugiura K; Naito K
    Sci Rep; 2019 Sep; 9(1):12878. PubMed ID: 31501500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The Development of SpCas9 Variants with High Specificity and Efficiency Based on the HH Theory].
    Wang GH; Wang CM; Wu XJ; Chu T; Huang DW; Li J
    Mol Biol (Mosk); 2024; 58(1):157-159. PubMed ID: 38943587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-throughput analysis of the activities of xCas9, SpCas9-NG and SpCas9 at matched and mismatched target sequences in human cells.
    Kim HK; Lee S; Kim Y; Park J; Min S; Choi JW; Huang TP; Yoon S; Liu DR; Kim HH
    Nat Biomed Eng; 2020 Jan; 4(1):111-124. PubMed ID: 31937939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural Plasticity of PAM Recognition by Engineered Variants of the RNA-Guided Endonuclease Cas9.
    Anders C; Bargsten K; Jinek M
    Mol Cell; 2016 Mar; 61(6):895-902. PubMed ID: 26990992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineered CRISPR-Cas9 nucleases with altered PAM specificities.
    Kleinstiver BP; Prew MS; Tsai SQ; Topkar VV; Nguyen NT; Zheng Z; Gonzales AP; Li Z; Peterson RT; Yeh JR; Aryee MJ; Joung JK
    Nature; 2015 Jul; 523(7561):481-5. PubMed ID: 26098369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural Basis for the Altered PAM Specificities of Engineered CRISPR-Cas9.
    Hirano S; Nishimasu H; Ishitani R; Nureki O
    Mol Cell; 2016 Mar; 61(6):886-94. PubMed ID: 26990991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA targeting by Clostridium cellulolyticum CRISPR-Cas9 Type II-C system.
    Fedorova I; Arseniev A; Selkova P; Pobegalov G; Goryanin I; Vasileva A; Musharova O; Abramova M; Kazalov M; Zyubko T; Artamonova T; Artamonova D; Shmakov S; Khodorkovskii M; Severinov K
    Nucleic Acids Res; 2020 Feb; 48(4):2026-2034. PubMed ID: 31943070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA interrogation by the CRISPR RNA-guided endonuclease Cas9.
    Sternberg SH; Redding S; Jinek M; Greene EC; Doudna JA
    Nature; 2014 Mar; 507(7490):62-7. PubMed ID: 24476820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR/Cas9 searches for a protospacer adjacent motif by lateral diffusion.
    Globyte V; Lee SH; Bae T; Kim JS; Joo C
    EMBO J; 2019 Feb; 38(4):. PubMed ID: 30573670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineered CRISPR/Cas9 enzymes improve discrimination by slowing DNA cleavage to allow release of off-target DNA.
    Liu MS; Gong S; Yu HH; Jung K; Johnson KA; Taylor DW
    Nat Commun; 2020 Jul; 11(1):3576. PubMed ID: 32681021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.